Stanford



Jennifer Caswell-Jin

Assistant Professor of Medicine (Oncology)

Medicine - Oncology

CLINICAL OFFICE (PRIMARY)

900 Blake Wilbur Dr

3rd Fl MC 6560

Stanford, CA 94305

Tel (650) 498-6000 **Fax** (650) 497-6813

Bio

BIO

Jennifer Caswell-Jin, MD is an Assistant Professor of Medicine (Oncology) specializing in breast cancer care and research. She received her medical degree from Harvard Medical School in 2010, completed her internal medicine residency at the University of California, San Francisco in 2013, and completed her clinical fellowship in medical oncology at Stanford Hospital & Clinics in 2017. Her clinical translational research program is aimed at developing personalized approaches to care that improve the outcomes of people with breast cancer.

CLINICAL FOCUS

- Medical Oncology

ACADEMIC APPOINTMENTS

- Assistant Professor-Univ Med Line, Medicine - Oncology
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- AACR Associate Member Award, San Antonio Breast Cancer Symposium (2018)
- Physician Scientist Training Award, Damon Runyon Cancer Research Foundation (2017)
- Postdoctoral Fellowship Award, Susan G. Komen (2017)
- ASCO Young Investigator Award, Conquer Cancer Foundation (2017)
- SCI Fellowship Award, Stanford Cancer Institute (2017)

PROFESSIONAL EDUCATION

- Residency: UCSF Dept of Internal Medicine (2013) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2018)
- Fellowship: Stanford University Hematology and Oncology Fellowship (2017) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2013)
- Medical Education: Harvard Medical School (2010) MA

- A.B., Harvard College , Biological Anthropology (2006)

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My research is on the translational application of next-generation sequencing technologies to breast cancer care: (1) the value of hereditary cancer genetic panel testing in clinical practice, (2) the mechanisms by which inherited genetic variants lead to breast cancer development, and (3) the analysis of somatic tumor sequencing data to inform understanding of breast tumorigenesis, metastasis, and development of resistance in response to therapeutics.

CLINICAL TRIALS

- Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies, Not Recruiting
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer, Not Recruiting
- Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer, Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Oncology (Fellowship Program)

Publications

PUBLICATIONS

- **Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Caswell-Jin, J. L., Somerfield, M. R., Khan, M. A., Kimmick, G. G., Gupta, S., Kenan, K., Peswani, N., Hershman, D. L., Ernst, B. J., Harvey, B. E., Krings, G., McAndrew, N. P., Riaz, et al
  2026: 101200JCO2602034

- **Analysis of Breast Cancer Mortality in the US-1975 to 2019.** *JAMA*
  Caswell-Jin, J. L., Sun, L. P., Munoz, D., Lu, Y., Li, Y., Huang, H., Hampton, J. M., Song, J., Jayasekera, J., Schechter, C., Alagoz, O., Stout, N. K., Trentham-Dietz, et al
  2024; 331 (3): 233-241

- **Quantifying cancer clinical trial eligibility using artificial Intelligence-Based matching.** *JNCI cancer spectrum*
  Goel, K., Myall, N. J., Dickerson, J., Caswell-Jin, J. L., Johnson, T., Worth, J. E., Gensheimer, M.
  2026

- **Modeling neoadjuvant treatment plus additional therapy effects on US population breast cancer mortality.** *Journal of the National Cancer Institute*
  Huang, X., Li, Y., Sarkar, S., Acharya, S., Huang, H., Groeneweg, R., Gil Quessep, E. J., Lipa, N., Song, J., Yang, Y., Sun, L., Lu, Y., Weedon-Fekjaer, et al
  2026

- **A clinical model incorporating early lymphocyte dynamics in HER2-positive breast cancer.** *Journal of the National Cancer Institute*
  Bergstrom, C. P., Luo, I., Bean, G. R., Kotler, E., Satoyoshi, M., Curtis, C., Kurien, S., Gomez, S. L., Kurian, A. W., Han, S. S., Caswell-Jin, J. L.
  2026

- **Adjuvant Trastuzumab Deruxtecan Versus Trastuzumab Emtansine by Residual Cancer Burden in HER2-Positive Early Breast Cancer: A Decision Analysis.** *medRxiv : the preprint server for health sciences*
  Fan, J., Tullberg, A. S., Kurian, A. W., Caswell-Jin, J. L., Dickerson, J. C., Alarid-Escudero, F.
  2026

- **College Attendance, Physical Disability, and Cervical Cancer Screening.** *JAMA network open*
  Harper, D. M., Lin, P. J., Young, A. P., Rehkopf, D. H., Vinson, A. H., Kalpakjian, C. Z., Caswell-Jin, J. L., McKee, M. M., Meade, M. A., Velasquez, E. E., Hao, S., Kamdar, N. S.
  2026; 9 (10): e2637495

- **Time on treatment for systemic therapies for patients with hormone receptor-positive breast cancer and BRCA1, BRCA2, or PALB2 pathogenic variants.**
  Parkinson, G., Nazari, S. S., Lustberg, M. B., Elliott, A., Sledge, G. W., Soto, A., Caswell-Jin, J., Kurian, A. W., Graff, S. L.
  LIPPINCOTT WILLIAMS & WILKINS.2026

- **Communication With Clinicians and Relatives About Cascade Genetic Testing in Cancer Patients With Germline Pathogenic Variants.** *JCO precision oncology*
  Kurian, A. W., Abrahamse, P., Furgal, A., Veenstra, C. M., Courser, R. R., Hofer, T. P., Hodan, R., Caswell-Jin, J. L., Gomez, S. L., Ward, K. C., Hamilton, A. S., Liu, L., An, et al
  2026; 10 (6): e2600041

- **Using large language models to extract diagnosis, recurrence, and death dates from breast cancer electronic medical records.**
  Dickerson, J., McClure, M., Shaw, M., Caswell-Jin, J.
  LIPPINCOTT WILLIAMS & WILKINS.2026: e13005

- **Correlates of patient enrollment in a population-based randomized controlled trial of cascade genetic testing in families with hereditary cancer susceptibility.**
  Katz, S. J., Abrahamse, P., Caswell-Jin, J., Veenstra, C. M., An, L. C., Kurian, A. W.
  LIPPINCOTT WILLIAMS & WILKINS.2026

- **Spatial organization of immune surveillance by germline mutation status in the Breast Cancer Family Registry.**
  McClure, M., Mangiante, L., Weiss, C., Ma, Z., Koo, J., John, E. M., Curtis, C., Kurian, A. W., Caswell-Jin, J.
  LIPPINCOTT WILLIAMS & WILKINS.2026

- **Clinical implementation of an online family cascade genetic testing platform: The Preventive Risk Outreach and Cascade Testing (PROACT) initiative.**
  Caswell-Jin, J., Hodan, R., Rios-Ventura, S., Donahue, J., Sharma, A., Zhang, A., An, L. C., Katz, S. J., Kurian, A. W.
  LIPPINCOTT WILLIAMS & WILKINS.2026

- **Mapping the contributions of adjuvant tamoxifen, 20 years later.** *Journal of the National Cancer Institute*
  Caswell-Jin, J. L., Plevritis, S. K., Kurian, A. W.
  2026

- **Guideline concordance in triple-negative breast cancer: What does it measure?** *Cancer*
  Caswell-Jin, J. L., Dickerson, J. C., Kurian, A. W.
  2026; 132 (7): e70381

- **Fully Automated Abstraction of Longitudinal Breast Oncology Records with Off-The-Shelf Large Language Models.** *medRxiv : the preprint server for health sciences*
  Dickerson, J. C., McClure, M. B., Shaw, M., Reitsma, M. B., Dalal, N. H., Kurian, A. W., Caswell-Jin, J. L.
  2026

- **Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy.** *Breast cancer research and treatment*
  Hammer, P. M., Enamandram, S., Ikeda, D. M., Lam, M. M., Wapnir, I. L., Chamberlain, E. D., Shaheen, S., Caswell-Jin, J. L., Itakura, H., Bean, G. R.
  2025; 215 (1): 10

- **Development and Validation of a Simulation Model-Based Tool to Support Individualized Physical Activity Discussions and Prescriptions for Breast Cancer Survivors** *JCO CLINICAL CANCER INFORMATICS*
  Jayasekera, J. C., Wilson, O. W. A., Schechter, C., Jin, J., Wojcik, K. M., van Ravesteyn, N. T., Wall, J., Schneider, J., D'Addario, L. L., Roh, J. M., Sarkar, S., Cadmus-Bertram, L., Pierce, et al
  2025; 9: e2500151

- **Reply to: Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

Dickerson, J. C., Caswell-Jin, J. L., Riaz, F., Goldhaber-Fiebert, J. D., Alarid-Escudero, F.
2025: JCO2501879

- **Physician Specialization and Receipt of Updated Breast Cancer Care in the United States: A SEER-Medicare Analysis.** *JCO oncology practice*
  Caswell-Jin, J. L., Reitsma, M. B., Tang, H., Dickerson, J. C., Phillips, S., John, E. M., Kurian, A. W., Staiger, B., Goldhaber-Fiebert, J. D.
  2025: OP2500462
- **Characterization of breast tumors and the tumor immune landscape in young, diverse participants of the Northern California Breast Cancer Family Registry**
  McClure, M., Mangiante, L., Simon, B. G., Weiss, C., Ma, Z., Koo, J., Ransohoff, J., John, E. M., Curtis, C., Caswell-Jin, J., Kurian, A. W.
  LIPPINCOTT WILLIAMS & WILKINS.2025: E12551
- **The accuracy and efficiency of large language models for chart review in cancer genetics.**
  Dickerson, J., Shaw, M., Satoyoshi, M., Rios-Ventura, S., Kingham, K., Kurian, A. W., Caswell-Jin, J.
  LIPPINCOTT WILLIAMS & WILKINS.2025: e22603
- **Association of driving distance to clinic with treatment route and dosing for metastatic breast cancer**
  Riaz, F., Luo, I., Satoyoshi, M., Dalal, N., John, E. M., Schapira, L., Caswell-Jin, J., Kurian, A. W.
  LIPPINCOTT WILLIAMS & WILKINS.2025: e13077
- **Association of germline homologous recombination deficiency mutations with HER2 status conversion from negative to positive following neoadjuvant chemotherapy in breast cancer.**
  Bergstrom, C. P., Troxell, M., Caswell-Jin, J., Bean, G., Allison, K. H., Telli, M. L.
  LIPPINCOTT WILLIAMS & WILKINS.2025: 1034
- **Cost and Cost-Effectiveness of Treating Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Dickerson, J. C., Moen, M. T., Nielsen, P., Riaz, F., Tran, E., Caswell-Jin, J. L., Suen, W., Goldhaber-Fiebert, J. D., Alarid-Escudero, F.
  2025: JCO2401960
- **Breast cancer risk modification in women with pathogenic variants in BRCA1, BRCA2, ATM, CHEK2 and PALB2.** *Cancer research communications*
  Kurian, A. W., Hughes, E., Bernhisel, R., Hu, E., Polley, E. C., Yadav, S., Hu, C., Caswell-Jin, J. L., John, E. M., Shadyab, A. H., Chlebowski, R., Nassir, R., Kraft, et al
  2025
- **Patient-Centered Research Through Artificial Intelligence to Identify Priorities in Cancer Care.** *JAMA oncology*
  Kim, J., Chen, M. L., Rezaei, S. J., Ramirez-Posada, M., Caswell-Jin, J. L., Kurian, A. W., Riaz, F., Sarin, K. Y., Tang, J. Y., Asch, S. M., Linos, E.
  2025
- **Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk.** *NPJ breast cancer*
  Sarkar, S., Schechter, C., Kurian, A. W., Caswell-Jin, J. L., Jayasekera, J., Mandelblatt, J. S.
  2025; 11 (1): 30
- **Mathematical Modeling to Address Questions in Breast Cancer Screening: An Overview of the Breast Cancer Models of the Cancer Intervention and Surveillance Modeling Network.** *Journal of breast imaging*
  Alagoz, O., Caswell-Jin, J. L., de Koning, H. J., Huang, H., Huang, X., Lee, S. J., Li, Y., Plevritis, S. K., Sarkar, S., Schechter, C. B., Stout, N. K., Trentham-Dietz, A., van Ravesteyn, et al
  2025
- **Complex rearrangements fuel ER+ and HER2+ breast tumours.** *Nature*
  Houlahan, K. E., Mangiante, L., Sotomayor-Vivas, C., Adimoelja, A., Park, S., Khan, A., Pribus, S. J., Ma, Z., Caswell-Jin, J. L., Curtis, C.
  2025
- **Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020.** *JAMA oncology*
  Goddard, K. A., Feuer, E. J., Mandelblatt, J. S., Meza, R., Holford, T. R., Jeon, J., Lansdorp-Vogelaar, I., Gulati, R., Stout, N. K., Howlader, N., Knudsen, A. B., Miller, D., Caswell-Jin, et al
  2024
- **Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights.** *JCO oncology practice*

Caswell-Jin, J. L., Freedman, R. A., Hassett, M. J., Tang, H., Garrett-Mayer, E., Somerfield, M. R., Giordano, S. H.
2024: OP2400663

- **The population-level effects of omitting chemotherapy guided by a 21-gene expression assay in node-positive breast cancer: a simulation modeling study.** *BMC cancer*
  Wojcik, K. M., Caswell-Jin, J. L., Wilson, O. W., Schechter, C., Kamil, D., Kurian, A. W., Jayasekera, J.
  2024; 24 (1): 975

- **Use of surgery for de novo metastatic breast cancer (mBC)**
  Dickerson, J., Tang, H., Thompson, C., Gomez, S. L., Satoyoshi, M., Kurian, A. W., Caswell-Jin, J.
  LIPPINCOTT WILLIAMS & WILKINS.2024

- **Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
  Freedman, R. A., Caswell-Jin, J. L., Hassett, M., Somerfield, M. R., Giordano, S. H.
  2024: JCO2400886

- **Collaborative Modeling to Compare Different Breast Cancer Screening Strategies: A Decision Analysis for the US Preventive Services Task Force.** *JAMA*
  Trentham-Dietz, A., Chapman, C. H., Jayasekera, J., Lowry, K. P., Heckman-Stoddard, B. M., Hampton, J. M., Caswell-Jin, J. L., Gangnon, R. E., Lu, Y., Huang, H., Stein, S., Sun, L., Gil Quessep, et al
  2024

- **US Breast Cancer Mortality-Reply.** *JAMA*
  Caswell-Jin, J. L., Kurian, A. W., Plevritis, S. K.
  2024

- **Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER plus metastatic breast cancer.**
  Rosen, E., Sharma, M., Berz, D., Caswell-Jin, J., Spira, A. I., Fulgar, G. A., Densel, M., Rana, N., Sperry, S., Warner, D., Meric-Bernstam, F., ASCO Authors' Grp
  LIPPINCOTT WILLIAMS & WILKINS.2023

- **Pharmacovigilance Analysis of HeartFailure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer.** *JACC. CardioOncology*
  Waliany, S., Caswell-Jin, J., Riaz, F., Myall, N., Zhu, H., Witteles, R. M., Neal, J. W.
  2023; 5 (1): 85-98

- **Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment.** *JNCI cancer spectrum*
  Kurian, A. W., Abrahamse, P., Hamilton, A. S., Caswell-Jin, J. L., Gomez, S. L., Hofer, T. J., Ward, K. C., Katz, S. J.
  2022

- **First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.**
  Meric-Bernstam, F., Sharma, M., Sommerhalder, D., Skeel, R. T., El-Khoueiry, A. B., Caswell-Jin, J., Patel, P. H., Rosen, E.
  LIPPINCOTT WILLIAMS & WILKINS.2022

- **Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in US women, 2000-2017.**
  Caswell-Jin, J., Sun, L., Munoz, D., Lu, Y., Li, Y., Huang, H., Hampton, J. M., Song, J., Jayasekera, J., Schechter, C., Alagoz, O., Stout, N. K., Trentham-Dietz, et al
  LIPPINCOTT WILLIAMS & WILKINS.2022

- **Breast cancer diagnosis and treatment during the COVID-19 pandemic in a nationwide, insured population.** *Breast cancer research and treatment*
  Caswell-Jin, J. L., Shafaee, M. N., Xiao, L., Liu, M., John, E. M., Bondy, M. L., Kurian, A. W.
  2022

- **Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.** *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*
  Bean, G. R., Najjar, S., Shin, S. J., Hosfield, E. M., Caswell-Jin, J. L., Urisman, A., Jones, K. D., Chen, Y., Krings, G.

2022

- **Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.** *Breast cancer research and treatment*
  Parikh, D. A., Kody, L., Brain, S., Heditsian, D., Lee, V., Curtis, C., Karin, M. R., Wapnir, I. L., Patel, M. I., Sledge, G. W., Caswell-Jin, J. L.
  2022

- **Twenty-one-gene recurrence score (RS) in germline (g)CHEK2 mutation-associated versus sporadic breast cancers (BC): A multi-site case-control study.**
  Afghahi, A., Marsh, S., Winchester, A., Gao, D., Parris, H., Axell, L., Ellisen, L. W., Hofstatter, E., Kurian, A. W., Wood, M., Zakalik, D., Mullin, C., Caswell-Jin, et al
  LIPPINCOTT WILLIAMS & WILKINS.2021

- **Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response** *NATURE CANCER*
  McNamara, K. L., Caswell-Jin, J. L., Joshi, R., Ma, Z., Kotler, E., Bean, G. R., Kriner, M., Zhou, Z., Hoang, M., Beechem, J., Zoeller, J., Press, M. F., Slamon, et al
  2021; 2 (4): 400-+

- **Androgen receptor agonists as breast cancer therapeutics.** *Nature medicine*
  Caswell-Jin, J. L., Curtis, C.
  2021

- **Molecular Heterogeneity and Evolution in Breast Cancer** *Annual review of cancer biology*
  Caswell-Jin, J. L., Lorenz, C., Curtis, C.
  2021; 5: 79-94

- **Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.** *Cancer*
  Kurian, A. W., Hughes, E., Simmons, T., Bernhisel, R., Probst, B., Meek, S., Caswell-Jin, J. L., John, E. M., Lanchbury, J. S., Slavin, T. P., Wagner, S., Gutin, A., Rohan, et al
  2021

- **Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.** *Cancer*
  Kurian, A. W., Hughes, E., Simmons, T., Bernhisel, R., Probst, B., Meek, S., Caswell-Jin, J. L., John, E. M., Lanchbury, J. S., Slavin, T. P., Wagner, S., Gutin, A., Rohan, et al
  2021

- **Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial**
  Caswell-Jin, J. L., McNamara, K. L., Dering, J., Chen, H., Dichmann, R., Perez, A., Patel, R., Kotler, E., Zoeller, J. J., Brugge, J. S., Press, M. F., Slamon, D. J., Curtis, et al
  AMER ASSOC CANCER RESEARCH.2020

- **Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).** *Nature communications*
  Hurvitz, S. A., Caswell-Jin, J. L., McNamara, K. L., Zoeller, J. J., Bean, G. R., Dichmann, R., Perez, A., Patel, R., Zehngebot, L., Allen, H., Bosserman, L., DiCarlo, B., Kennedy, et al
  2020; 11 (1): 5824

- **Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.** *JAMA*
  Kurian, A. W., Bernhisel, R. n., Larson, K. n., Caswell-Jin, J. L., Shadyab, A. H., Ochs-Balcom, H. n., Stefanick, M. L.
  2020; 323 (10): 995–97

- **Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.** *JAMIA Open*
  Ling, A. Y., Kurian, A. W., Caswell-Jin, J. L., Sledge, G. W., Shah, N. H., Tamang, S. R.
  2019: 528-537

- **Re: Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative Response** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
  Caswell-Jin, J. L., Kurian, A. W.
  2019; 111 (8): 874

- **Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.** *Nature*
  Rueda, O. M., Sammut, S., Seoane, J. A., Chin, S., Caswell-Jin, J. L., Callari, M., Batra, R., Pereira, B., Bruna, A., Ali, H. R., Provenzano, E., Liu, B., Parisien, et al
  2019

- **Using natural language processing to construct a metastatic breast cancer cohort from linked cancer registry and electronic medical records data.** *JAMIA open*
  Ling, A. Y., Kurian, A. W., Caswell-Jin, J. L., Sledge, G. W., Shah, N. H., Tamang, S. R.
  2019; 2 (4): 528–37

- **Cascade Genetic Testing of Relatives for Hereditary Cancer Risk: Results of an Online Initiative** *JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE*
  Caswell-Jin, J. L., Zimmer, A. D., Stedden, W., Kingham, K. E., Zhou, A. Y., Kurian, A. W.
  2019; 111 (1): 95–98

- **Chromatin regulators mediate anthracycline sensitivity in breast cancer.** *Nature medicine*
  Seoane, J. A., Kirkland, J. G., Caswell-Jin, J. L., Crabtree, G. R., Curtis, C. n.
  2019

- **Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.** *Nature communications*
  Caswell-Jin, J. L., McNamara, K. n., Reiter, J. G., Sun, R. n., Hu, Z. n., Ma, Z. n., Ding, J. n., Suarez, C. J., Tilk, S. n., Raghavendra, A. n., Forte, V. n., Chin, S. F., Bardwell, et al
  2019; 10 (1): 657

- **Natural Language Processing Approaches to Detect the Timeline of Metastatic Recurrence of Breast Cancer.** *JCO clinical cancer informatics*
  Banerjee, I. n., Bozkurt, S. n., Caswell-Jin, J. L., Kurian, A. W., Rubin, D. L.
  2019; 3: 1–12

- **Response to Peshkin, Isaacs, and Schwartz.** *Journal of the National Cancer Institute*
  Caswell-Jin, J. L., Kurian, A. W.
  2019

- **Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review.** *JNCI cancer spectrum*
  Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., Kurian, A. W.
  2018; 2 (4): pky062

- **Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?** *JCO precision oncology*
  Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W.
  2018; 2: 1-10

- **Pathogenic variants in less familiar cancer susceptibility genes: what happens after genetic testing?** *JCO Precision Oncology*
  Hall, E. T., Parikh, D., Caswell-Jin, J. L., Gupta, T., Mills, M. A., Kingham, K. E., Koff, R., Ford, J. M., Kurian, A. W.
  2018

- **Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk.** *Genetics in medicine : official journal of the American College of Medical Genetics*
  Caswell-Jin, J. L., Gupta, T. n., Hall, E. n., Petrovchich, I. M., Mills, M. A., Kingham, K. E., Koff, R. n., Chun, N. M., Levonian, P. n., Lebensohn, A. P., Ford, J. M., Kurian, A. W.
  2017

- **Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.** *Journal of oncology practice / American Society of Clinical Oncology*
  Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., Hofmann, L. V., Neal, J. W., Telli, M. L.
  2016; 12 (8): 763-764

- **Multiple breast cancer risk variants are associated with differential transcript isoform expression in tumors** *HUMAN MOLECULAR GENETICS*
  Caswell, J. L., Camarda, R., Zhou, A. Y., Huntsman, S., Hu, D., Brenner, S. E., Zaitlen, N., Goga, A., Ziv, E.
  2015; 24 (25): 7421-7431

- **Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients** *NATURE COMMUNICATIONS*
  Ziv, E., Dean, E., Hu, D., Martino, A., Serie, D., Curtin, K., Campa, D., Aftab, B., Bracci, P., Buda, G., Zhao, Y., Caswell-Jin, J., Diasio, et al
  2015; 6
- **Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25** *NATURE COMMUNICATIONS*
  Fejerman, L., Ahmadiyeh, N., Hu, D., Huntsman, S., Beckman, K. B., Caswell, J. L., Tsung, K., John, E. M., Torres-Mejia, G., Carvajal-Carmona, L., Echeverry, M. M., Tuazon, A. M., Ramirez, et al
  2014; 5
- **High mammographic density in women of Ashkenazi Jewish descent** *BREAST CANCER RESEARCH*
  Caswell, J. L., Kerlikowske, K., Shepherd, J. A., Cummings, S. R., Hu, D., Huntsman, S., Ziv, E.
  2013; 15 (3)
- **8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
  Ahmadiyeh, N., Pomerantz, M. M., Grisanzio, C., Herman, P., Jia, L., Almendro, V., He, H. H., Brown, M., Liu, X. S., Davis, M., Caswell, J. L., Beckwith, C. A., Hills, et al
  2010; 107 (21): 9742-9746
- **Analysis of chimpanzee history based on genome sequence alignments** *PLOS GENETICS*
  Caswell, J. L., Mallick, S., Richter, D. J., Neubauer, J., Gnerre, C. S., Gnerre, S., Reich, D.
  2008; 4 (4)